Article Text

PDF
CP-216 Factors influencing the selection of direct acting antivirals in the treatment of genotype 1 hepatitis C virus infection
  1. R García-Paricio1,
  2. E González-Colominas1,
  3. D Echeverría-Esnal1,
  4. D Conde-Estevez1,
  5. M De Antonio-Cuscó1,
  6. O Ferrandez1,
  7. JA Carrión2,
  8. E Salas1,
  9. S Luque1
  1. 1Hospital Del Mar, Pharmacy Department, Barcelona, Spain
  2. 2Hospital Del Mar, Liver Section — Gastroenterology Department, Barcelona, Spain

Abstract

Background The recent approval of the new direct acting antivirals (DAAs) has extended treatment options in hepatitis C virus (HCV) genotype 1 infected patients with compensated liver disease.

Purpose To evaluate which factors can influence the selection of DAAs in genotype 1 HCV patients in our setting.

Material and methods Retrospective study including genotype 1 HCV patients treated with interferon free DAAs from December 2014 to September 2015. Data collected: demographics, genotype 1 subtype, HIV infection, presence of liver cirrhosis (LC), prior treatment status (naïve or pretreated) and other concomitant drugs. DAAs were classified­ as follows: sofosbuvir+simeprevir±ribavirin (SOF/SMV); sofosbuvir+daclatasvir±ribavirin (SOF/DCV); sofosbuvir/ledipasvir±ribavirin (SOF/LDV); ombitasvir/paritaprevir/ritonavir+dasabuvir±RBV (OBV/PTV/r/DSV). The χ2 test and the Mann-Whitney U test were used for categorical and quantitative variables, respectively.

Results We included 124 patients: 79 (63.7%) male; mean age 60.8 (±SD 11.5) years; 35 (28.2%) genotype 1a; 26 (21%) HIV/HCV coinfected; 79 (63.7%) LC; 65 (52.4%) naïve; and 56 (45.2%) with polypharmacy (>3 drugs, median value).

DAA regimen selected: 34 (27.4%) SOF/SMV; 14 (11.3%) SOF/DCV; 34 (27.4%) SOF/LDV and 42 (33.9%) OBV/PTV/r/DSV. There were statistically significant differences in the frequency distribution of the different selected DAAs (table 1)

View this table:
Abstract CP-216 Table 1

A tendency was observed when comparing different genotype subtypes (p = 0.094) or presence of polypharmacy (p = 0.088).

Conclusion HIV/HCV coinfected and cirrhotic patients were more likely to be treated with SOF/LDV while HCV monoinfected and non-cirrhotic patients with likely to receive OBV/PTV/r/DSV. Pretreated patients were more likely to be treated with SOF/SMV while those naïve with more likely to receive OBV/PTV/r/DSV.

The major potential for drug-drug interactions of OBV/PTV/r/DSV and its lower experience in advanced liver disease and previous triple therapy failure could have influenced these findings.

References and/or Acknowledgements

  1. Pawlotsky JM. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015

References and/or AcknowledgementsNo conflict of interest.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.